EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of Oncotype DX risk categorization and receipt of chemotherapy on survival outcomes among patients with small node-negative HR+ breast cancer

Andrea House, Julie A Stephens, Robert Wesolowski, Sachin R Jhawar, Arya Marium Roy, Nerea Lopetegui-Lia, Dionisia Quiroga, Ashley P Davenport, Gilbert Bader, Nicole Williams, Sagar Sardesai, Daniel G Stover und 2 weitere

The Oncologist · 08.07.2026 · 31 (8)

DOI: 10.1093/oncolo/oyag276 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, online erschienen am 15.07.2026. Verfasst von Andrea House und 13 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine, The Ohio State University, Columbus, OH, 43210, United States. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The application of genomic assays, such as Oncotype DX, in patients with small (T1mi/a/b) clinically node-negative (N0-N1mi) hormone receptor positive breast cancer (HR+BC) is becoming increasingly popular in real-world clinical practice. Whether these results can be reliably prognostic among this clinically low-risk population and can be used to make decisions on the application of adjuvant chemotherapy remains unknown. Patients and methods Data from the National Cancer Database (NCDB) were examined for those diagnosed with small, node-negative HR+BC between 2010 and 2020. Oncotype DX recurrence score (RS) data were classified as low (RS < 11), intermediate (RS = 11-25), or high risk (RS = 26-100). Our primary objective was comparing overall survival (OS) based on chemotherapy receipt for those with high-risk scores. Kaplan-Meier methods and multivariable Cox proportional hazard models were used. Propensity score matching was additionally performed.

Results

Of the 350 911 patients with T1mi/a/b N0/N0(i+)/N1mi HR+BC, 102 357 (29.2%) underwent Oncotype DX testing and had available RS data. Among them, 32 158 (31.4%) had low, 58 891 (57.5%) had intermediate, and 11 308 (11.0%) had high-risk. Chemotherapy receipt was documented in 1.2% (n = 402) of low-risk, 6.8% (n = 4000) of intermediate-risk, and 66.3% (n = 7496) of high-risk patients. Among high-risk patients, those who received chemotherapy had a lower risk of death compared with those in the chemotherapy omission arm, both on univariate (HR, 0.55; 95% CI, 0.52-0.72; P < 0.001) and multivariable (HR, 0.61; 95% CI, 0.52-0.72; P < 0.001) analyses. This finding remained true following propensity score matching (univariate HR, 0.63; 95% CI, 0.52-0.76; aHR, 0.71; 95% CI, 0.59-0.86; P < 0.001 for both). Factors associated with a high RS included higher tumor grade, Black race, and lymphovascular invasion.

Conclusion

Our findings suggest that risk stratification through a genomic assay such as Oncotype DX may be advantageous, even among otherwise clinically low-risk individuals with HR + BC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsHumansFemaleMiddle AgedPrognosisAgedChemotherapy, AdjuvantNeoplasm Recurrence, LocalAdult

Stichwörter der Autor:innen

Oncotype DXT1bchemotherapyhormone receptor-positive breast cancernational cancer databasenode-negative

Autor:innen und Institutionen

  • College of Medicine, The Ohio State University, Columbus, OH, 43210, United States.
  • Center for Biostatistics, The Ohio State University, Columbus, OH, 43210, United States.
  • Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, 43210, United States.
  • Department of Radiation Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, 43210, USA.

ORCID-Profile: Margaret E Gatti-Mays, Kai C C Johnson

Zitieren

APA

House, A., Stephens, J. A., Wesolowski, R., Jhawar, S. R., Roy, A. M., Lopetegui-Lia, N., Quiroga, D., Davenport, A. P., Bader, G., Williams, N., Sardesai, S., Stover, D. G., Gatti-Mays, M. E., & Johnson, K. C. C. (2026). Impact of Oncotype DX risk categorization and receipt of chemotherapy on survival outcomes among patients with small node-negative HR+ breast cancer. The Oncologist, 31(8). https://doi.org/10.1093/oncolo/oyag276

Vancouver

House A, Stephens JA, Wesolowski R, Jhawar SR, Roy AM, Lopetegui-Lia N, et al. Impact of Oncotype DX risk categorization and receipt of chemotherapy on survival outcomes among patients with small node-negative HR+ breast cancer. The Oncologist. 2026;31(8). doi:10.1093/oncolo/oyag276

BibTeX
@article{House2026,
  author = {House, Andrea and Stephens, Julie A and Wesolowski, Robert and Jhawar, Sachin R and Roy, Arya Marium and Lopetegui-Lia, Nerea and Quiroga, Dionisia and Davenport, Ashley P and Bader, Gilbert and Williams, Nicole and Sardesai, Sagar and Stover, Daniel G and Gatti-Mays, Margaret E and Johnson, Kai C C},
  title = {Impact of Oncotype DX risk categorization and receipt of chemotherapy on survival outcomes among patients with small node-negative HR+ breast cancer},
  journal = {The Oncologist},
  year = {2026},
  volume = {31},
  number = {8},
  doi = {10.1093/oncolo/oyag276}
}
Kostenlos starten →